Progress of the development of anti-COVID-19 drugs
10.16438/j.0513-4870.2022-0707
- VernacularTitle:抗COVID-19药物的研究进展
- Author:
Li-ping LIN
1
;
Fei TANG
1
,
2
;
Rui-an XU
1
;
Xiu-ling CUI
1
Author Information
1. Engineering Research Center of the Ministry of Education for Molecular Drugs, Fujian Key Laboratory of Molecular Medicine, Fujian Key Laboratory of Precision Medicine and Molecular Diagnosis, Xiamen Key Laboratory of Marine and Genetic Drugs, College of Biomedicine, Huaqiao University, Xiamen 361021, China
2. Xiamen Center for Disease Control and Prevention, Xiamen 361021, China
- Publication Type:Research Article
- Keywords:
COVID-19;
target;
medication;
rug repurposing;
rug discovery
- From:
Acta Pharmaceutica Sinica
2023;58(1):39-51
- CountryChina
- Language:Chinese
-
Abstract:
Since the outbreak of the novel coronavirus (SARS-CoV-2) disease COVID-19 (also known as 2019-nCoV) caused by SARS-CoV-2 in the end of 2019, it has spread rapidly in worldwide. Besides developing effective vaccines, it is urgent to develop safe and effective anti-SARS-CoV-2 drugs to fight this disease. Paxlovid, molnupiravir, sotrovimab and bebtelovimab are urgently authorized by FDA have been proved to be effective against Omicron. This manuscript mainly reviews the recent progress of effective inhibitors against the virus in the world, including receptor inhibitors, antibodies, natural product inhibitors, synthetic inhibitors and broad-spectrum antiviral drugs that are effective against other RNA viruses.
